Popular GLP-1 medications are widely used across the United States for diabetes, weight loss, and various chronic conditions such as cardiovascular disease and sleep apnea. However, recent data indicates that millions of Americans are taking these potent peptide-based drugs in unapproved ways, prompting concerns about safety and real-world effectiveness.
CDC Survey Reveals Scale of GLP-1 Usage and Alterations
According to a study published by researchers at the Centers for Disease Control and Prevention, approximately 9.8 percent of US adults—translating to about 27 million people—used a glucagon-like peptide-1 receptor agonist in 2025. The findings were derived from survey data collected between July and August of 2025 involving over 8,000 American adults and appeared in the CDC’s Morbidity and Mortality Weekly Report.
The study found that nearly half, or 44 percent, of GLP-1 users altered their medication regimens. Patients reported skipping doses, delaying prescription refills, and taking smaller doses than recommended by physicians.
Cost and Compounded Drugs Drive Modifications
Financial constraints and supply shortages were primary drivers for altering medication use, with over half of those modifying their regimens citing cost or availability as the reason. These barriers heavily affected younger demographics, as 58 percent of adults aged 14 to 39 who changed their usage pointed to cost, compared to only 20 percent of adults aged 65 and older.
Additionally, modified usage occurred frequently among individuals taking non-standard treatments. At least 23 percent of all GLP-1 users relied on compounded versions of the medications, while an additional 9 percent were uncertain whether their prescribed drug was compounded or not.








